Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD,...
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (E...
In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF o...
Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & ...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allos...
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,...
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2...
Beactica Therapeutics AB, a Swedish precision medicine company, announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which ...
AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its propri...
InSilicoTrials, a cloud-based platform for AI and computational modeling and simulation in healthcare, today announced that it is a subawardee on a team ...
Marsico Pancreatic Cancer Initiative at CU Anschutz expands across institutions, pairing single-cell and spatial profiles with longitudinal outcomes fr...
– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS® System to Firefly’s nationwide network of Evoke™ cl...
If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval ...
Astellas Pharma Inc.announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-t...
© 2026 Biopharma Boardroom. All Rights Reserved.
